Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.106 - hepsin and Organism(s) Homo sapiens and UniProt Accession P05981

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Effect of anthralin on cell viability in human prostate adenocarcinoma.
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Adenomatous Polyposis Coli
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
Breast Neoplasms
Bispecific antibodies: a novel approach for targeting prominent biomarkers.
Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.
Clinical and Biological Significance of Hepsin Overexpression in Breast Cancer.
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Hepsin regulates TGF? signaling via fibronectin proteolysis.
Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
Carcinogenesis
A statistical method for identifying differential gene-gene co-expression patterns.
Decreased expressions of hepsin in human hepatocellular carcinomas.
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth.
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
The Role of Hepsin in Endometrial Carcinoma.
Carcinoma
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma.
Expression profiling reveals hepsin overexpression in prostate cancer.
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
The Role of Hepsin in Endometrial Carcinoma.
Carcinoma, Endometrioid
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Carcinoma, Hepatocellular
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells.
Decreased expressions of hepsin in human hepatocellular carcinomas.
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth.
Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues.
N-glycan in the scavenger receptor cysteine-rich domain of hepsin promotes intracellular trafficking and cell surface expression.
Carcinoma, Renal Cell
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma.
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
Congenital Abnormalities
Thyroxine treatments do not correct inner ear defects in tmprss1 mutant mice.
Endometrial Hyperplasia
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
The Role of Hepsin in Endometrial Carcinoma.
Endometrial Neoplasms
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Hepsin inhibits the cell growth of endometrial cancer.
The Role of Hepsin in Endometrial Carcinoma.
Endometriosis
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.
Hearing Loss
An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss.
Hepsin: a multifunctional transmembrane serine protease in pathobiology.
Thyroxine treatments do not correct inner ear defects in tmprss1 mutant mice.
Hepatitis B
Decreased expressions of hepsin in human hepatocellular carcinomas.
Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes.
Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin.
hepsin deficiency
Gene targeting in hemostasis. Hepsin.
Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease.
Hepsin enhances liver metabolism and inhibits adipocyte browning in mice.
Hepsin Promotes Epithelial-Mesenchymal Transition and Cell Invasion Through the miR-222/PPP2R2A/AKT Axis in Prostate Cancer.
Hepsin: a multifunctional transmembrane serine protease in pathobiology.
Herpes Zoster
The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin.
Immune System Diseases
Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Kidney Calculi
Design of drug-like hepsin inhibitors against prostate cancer and kidney stones.
Lymphatic Metastasis
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Neoplasm Metastasis
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Allosteric antibody inhibition of human hepsin protease.
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells.
Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Hepsin and prostate cancer.
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Hepsin paradox reveals unexpected complexity of metastatic process.
Hepsin promotes prostate cancer progression and metastasis.
Identification and characterization of small-molecule inhibitors of hepsin.
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Recent Advances of Hepsin-Targeted Inhibitors.
Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells via hepatocyte growth factor signaling.
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Neoplasms
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
A statistical method for identifying differential gene-gene co-expression patterns.
Allosteric antibody inhibition of human hepsin protease.
An allosteric anti-hepsin antibody derived from a constrained phage display library.
Analyzing the Type II Transmembrane Serine Protease Hepsin-Dependent Basement Membrane Remodeling in 3D Cell Culture.
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells.
Clinical and Biological Significance of Hepsin Overexpression in Breast Cancer.
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Coagulation proteases and human cancer.
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Design of drug-like hepsin inhibitors against prostate cancer and kidney stones.
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.
Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Effect of anthralin on cell viability in human prostate adenocarcinoma.
Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.
Expression of genes and proteins specific for prostate cancer.
Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Expression profiling reveals hepsin overexpression in prostate cancer.
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Hepsin and prostate cancer.
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Hepsin paradox reveals unexpected complexity of metastatic process.
Hepsin regulates TGF? signaling via fibronectin proteolysis.
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Hepsin: a multifunctional transmembrane serine protease in pathobiology.
High Hepsin expression predicts poor prognosis in Gastric Cancer.
Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin.
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
Microarray analysis in prostate cancer research.
N-glycan in the scavenger receptor cysteine-rich domain of hepsin promotes intracellular trafficking and cell surface expression.
Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.
pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation.
Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells via hepatocyte growth factor signaling.
SPINT2 Deregulation in Prostate Carcinoma.
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
The Role of Hepsin in Endometrial Carcinoma.
The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.
The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain.
Obesity
Hepsin enhances liver metabolism and inhibits adipocyte browning in mice.
Ovarian Neoplasms
Analyzing the Type II Transmembrane Serine Protease Hepsin-Dependent Basement Membrane Remodeling in 3D Cell Culture.
Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines.
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Identification of Hepsin and Protein Disulfide Isomerase A3 as Targets of Gelatinolytic Action in Rat Ovarian Granulosa Cells During the Periovulatory Period.
Prostatic Hyperplasia
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Prostatic Neoplasms
Allosteric antibody inhibition of human hepsin protease.
Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
An allosteric anti-hepsin antibody derived from a constrained phage display library.
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Association of hepsin gene variants with prostate cancer risk and prognosis.
Biomarkers for prostate cancer detection.
Bispecific antibodies: a novel approach for targeting prominent biomarkers.
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
Correction: Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.
Design of drug-like hepsin inhibitors against prostate cancer and kidney stones.
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Detection of early prostate cancer using a hepsin-targeted imaging agent.
Development of an Activatable Fluorescent Probe for Prostate Cancer Imaging.
Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Enzyme cleavable nanoparticles from peptide based triblock copolymers.
Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.
Expression profiling reveals hepsin overexpression in prostate cancer.
From in-silico to Experimental Validation: Tailoring Peptide Substrates for a Serine Protease.
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Hepsin and prostate cancer.
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.
Hepsin in the diagnosis of prostate cancer.
Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2? phosphorylation in prostate cancer.
HEPSIN inhibits cell growth/invasion in prostate cancer cells.
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Hepsin paradox reveals unexpected complexity of metastatic process.
Hepsin Promotes Epithelial-Mesenchymal Transition and Cell Invasion Through the miR-222/PPP2R2A/AKT Axis in Prostate Cancer.
Hepsin promotes prostate cancer progression and metastasis.
HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer Immunotherapy.
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Identification and characterization of small-molecule inhibitors of hepsin.
Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing.
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues.
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease.
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Recent Advances of Hepsin-Targeted Inhibitors.
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
The Role of Hepsin in Endometrial Carcinoma.
TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.
Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
Variants in the HEPSIN gene are associated with prostate cancer in men of European origin.
Variants in the HEPSIN gene are associated with susceptibility to prostate cancer.
[Markers for diagnosis, prediction and prognosis of prostate cancer]
Sarcoma
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Stomach Neoplasms
High Hepsin expression predicts poor prognosis in Gastric Cancer.
Synovitis
The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.
Urologic Neoplasms
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Virus Diseases
The transmembrane serine protease hepsin suppresses type I interferon induction by cleaving STING.